Novel cell metabolism modulating compounds and uses thereof

Abstract

A class of compounds that bind to fatty acid binding protein (FABP4) and modulate adipocyte metabolism to drive enhanced glucose utilization, as well as pharmaceutical compositions comprising the class of compounds, in combination with a pharmaceutically acceptable diluent or carrier, and optionally, further in combination with a therapeutically active agent, and the use of these compounds in medicine and for the preparation of a medicament in the treatment of disorders acting on the FABP4.

Description

[0001] NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF

[0002] Cross-Reference to Related Applications Section

[0003] This application claims priority to U.S. Provisional Patent Application S / N 62 / 963,508 filed on January 20, 2020, the entire contents of which are hereby incorporated by reference in their entirety.

[0004] Field of the Embodiments

[0005] The field of the embodiments of the present invention relate to novel compounds for treatment or prophylaxis of diseases related to metabolism and inflammation, including, but not limited to, type-2 diabetes, atherosclerosis, intracranial atherosclerotic disease, Alzheimer’s disease, non-alcoholic steatohepatitis, obesity, cardiovascular disease, asthma, cancer and other diseases. Compounds in this invention particularly interact with fatty acid binding protein 4 (FABP4) and improve glucose consumption in adipocytes.

[0006] Background of the Embodiments

[0007] Fatty acid binding proteins (FABP) are a family of proteins that reversibly bind free fatty acids and other lipid molecules and facilitate their transport in cells. To date, nine different FABP isoforms have been identified in mammals. FABP isoforms display differential expression patterns in different tissues. Fatty acid binding protein 4 (FABP4), also often referred to as aP2 in literature, is primarily expressed in adipocytes and macrophages, and mediates key metabolic and inflammatory pathways in these cells, such as lipid storage and degradation, signaling, and eicosanoid production. In addition, FABP4 is also secreted to plasma and has been proposed to act as an adipose-derived factor regulating systemic glucose homeostasis.

[0008] Genetic knockout studies in mice provided insights into tissue-specific and systemic functions of FABP4. Importantly, when mice bearing a homozygous deletion of the FABP4 gene are subjected to a prolonged high-fat diet, they gained weight comparable to the wild-type, but were protected from hyperglycemia and insulin-resistance. See, G. S. Hotamisligil, et al., “Uncoupling of Obesity from Insulin Resistance Through a Targeted Mutation in Ap2, the Adipocyte Fatty Acid Binding Protein,” Science, 1996, 274(5291), Pages 1377-9, doi:

[0009] 10.1126 / science.274.5291.1377. In addition, FABP4-deficiency significantly protected apoliprotein E (ApoE) knockout mice from atherosclerosis, a phenotype attributed to FABP4 modulation of inflammatory pathways in macrophages. See, L. Makowski, et al., “Lack of Macrophage Fatty -Acid-Binding Protein aP2 Protects Mice Deficient in Apolipoprotein E Against Atherosclerosis,” Nat. Med. 2001, 7(6), Pages 699-705, doi: 10.1038 / 89076. FABP4 expression has also been detected in airway epithelial cells and FABP4-deficiency was demonstrated to be protective in a mouse model of allergic lung inflammation. See, B. O.V. Shum, et al., “The Adipocyte Fatty Acid-Binding Protein aP2 is Required in Allergic Airway Inflammation,” J. Clin. Invest., 2006, 116(8), Pages 2183-2192, doi: 10.1172 / JCI24767.

[0010] Several reports have been published in literature linking FABP4 expression level and functions with a number of pathologies in humans. For instance, reduced risk of type-2 diabetes and coronary heart disease was observed in individuals bearing genetic variations in the promoter region of FABP4 (rs77878271) that resulted in reduced expression of this gene. See, G. Tuncman, et al., “A Genetic Variant at the Fatty Acid-binding Protein aP2 Locus Reduces the Risk for Hypertriglyceridemia, Type 2 Diabetes, and Cardiovascular Disease,” Proc. Natl. Acad. Sci. USA, 2006, 103(18), Pages 6970-5, doi: 10.1073 / pnas.0602178103. The same polymorphism was also associated with reduced atherosclerotic disease manifestations in an independent study. See, J. Saksi, et al., “Low-Expression Variant of Fatty Acid-Binding Protein 4 Favors Reduced Manifestations of Atherosclerotic Disease and Increased Plaque Stability,” Circ. Cardiovasc. Genet., 2014, 7(5), Pages 588-98, doi: 10.1161 / CIRCGENETICS.113.000499. Furthermore, triple-negative breast cancer patients with a single nucleotide polymorphism in the 3’ untranslated region (UTR) of FABP4 (rsl054135-GG genotype) that also results in reduced FAB4 expression was associated with a reduced risk of disease progression and a prolonged disease-free survival time. See, W. Wang, et al., “A Single-Nucleotide Polymorphism in the 3'- UTR Region of the Adipocyte Fatty Acid Binding Protein 4 Gene is Associated with Prognosis of Triple-Negative Breast Cancer,” Oncotarget, 2016, 7(14), Pages 18984-18998, doi: 10.18632 / oncotarget.7920. Moreover, increased expression of FABP4 has been observed in preeclamptic placenta and is proposed to have a role in the pathogenesis of preeclampsia. See, Y. Yan, et al., “Increased Expression of Fatty Acid Binding Protein 4 in Preeclamptic Placenta and its Relevance to Preeclampsia,” Placenta, 2016, 39, Pages 94-100, https: / / doi.Org / 10.1016 / j.placenta.2016.01.014. Similarly, granulosa cells of polycystic ovary syndrome patients also show increased FABP4 expression, which was related to the clinical characterization of the disease. See, W. Hu, et al., “Expression and Regulation of Adipocyte Fatty Acid Binding Protein in Granulosa Cells and its Relation with Clinical Characteristics of Polycystic Ovary Syndrome,” Endocrine, 2011, 40(2), Pages 196-202, doi: 10.1007 / sl2020-011- 9495-9. Collectively, these studies demonstrated the active role of FAPB4 in regulating systemic metabolism and inflammation, and suggested that pharmacological targeting of FABP4 can be used as a strategy for the treatment of a variety of diseases linked to FABP4 functions.

[0011] Adipocytes play a central role in the systemic glucose homeostasis. One of their primary roles is taking up excess glucose in plasma and storing it in the form of lipids. Adipocyte dysfunction due to metabolic stress and inflammation often leads to complications, such as hyperglycemia and insulin resistance. It is noteworthy that FABP4-deficient mice showed increased glucose deposition to adipose tissue. Adipocytes isolated from these animals showed a significantly elevated rate of glucose conversion into fatty acids as compared to their wild-type counterparts. See, S. Shaughnessy, et al., “Adipocyte Metabolism in Adipocyte Fatty Acid Binding Protein Knockout Mice (Ap2- / -) After Short-Term High-Fat Feeding: Functional Compensation by the Keratinocyte [Correction Of Keritinocyte] Fatty Acid Binding Protein,” Diabetes, 2000, 49(6), Pages 904-911, https: / / doi.Org / 10.2337 / diabetes.49.6.904. Thus, increasing glucose consumption in adipocytes can be achieved by targeting FABP4.

[0012] While the literature and certain prior art patent applications (e.g., WO 00 / 47734, WO 00 / 15229, WO 00 / 15230, WO 02 / 40448, WO 01 / 54694, WO 00 / 59506, and WO 2004 / 063156) have provided various presentations of the concept of the FABP inhibition, in general, and that of the FABP4 inhibition, in particular, none of the discussions in these prior art documents provides solution(s) of all of the unmet needs, as does the present invention. Specifically, the present invention describes a novel class of compounds that bind to FABP4 and modulate adipocyte metabolism to drive enhanced glucose utilization. Summary of the Embodiments

[0013] The present invention, in one of its embodiments, relates to a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof: wherein each of R1and R6-R9are independently -H, -CN, -COOH, -CONH2, B(ORa)2, an acid isostere, a halo, Cnalkyl, Cnalkenyl, Cnalkynyl, Cnaryl, Cnaminoalkyl, Cnhaloalkyl, Cnheteroaryl, Cncycloalkyl, or Cnheterocycloalkyl, wherein Raof the B(ORa)2is H or an alkyl, wherein B of the B(ORa)2is boron, wherein n of the Cnis 1 - 10, wherein each of R2- R5are independently -H, -CN, -COOH, -COOMe, -CONH2, B(ORa)2, the acid isostere, the halo, -CONHOH, -NH-S02-C1-C6-alkyl, -NHS02Ar, the Cnalkyl, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, the Cnaryl, the Cnaminoalkyl, the Cnhaloalkyl, the Cnheteroaryl, the Cncycloalkyl, or the Cnheterocycloalkyl, wherein the Ar of - HS02Ar is selected from the group consisting of: phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3- benzoxadi azole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-l,4-benzoxazine, 1,5- naphthyridine, 1,8-naphthyridine, acridine, phenazine, and xanthene, wherein each of the Cnalkyl, the Cnalkenyl, the Cnalkynyl, the Cnaryl, the Cnaminoalkyl, the Cnhaloalkyl, the Cnheteroaryl, the Cncycloalkyl, and the Cnheterocycloalkyl is unsubstituted or substituted with a quantity of substituents being between 1-5, wherein each of the substituents is the same or different, wherein each of the substituents is selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, and -Cq-U- wherein each q of -Cq-U-Cqis independently 0 to 10, wherein the U of -Cq-U-Cqis any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, S02, or N(R1)(R1), wherein each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, the Cnaryl, the Cnaminoalkyl, the Cnhaloalkyl, the Cnheteroaryl, the Cncycloalkyl, or the Cnheterocycloalkyl, wherein each R1of N(R1)(R1) is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, wherein Q is a bond or O, wherein X is C, N, O, or S such that R6is not present if X is O or S, wherein “A” is a saturated or unsaturated ring depicted by wherein Y, T, W, and Z are independently a bond, C, N, O an alkyl having 1 to 4 carbon atoms, or an alkenyl having 1 to 4 carbon atoms, and wherein n is 0, 1, 2, or 3.

[0014] In one embodiment, the invention comprises the compound of Formula I where at least one of R1and R2, R2and R3, R3and R4, R4and R5, R6and R7, R7and R8, R8and R9are bonded forming a fused heteroaryl or fused heterocycloalkyl.

[0015] In a further embodiment, the invention may be a compound of Formula II or pharmaceutically acceptable salts or esters thereof:

[0016] Formula II wherein R1and R6-R9is independently -H, -CN, -COOH, -CONH2, B(ORa)2, an acid isostere, a halo, Cnalkyl, Cnalkenyl, Cnalkynyl, Cnaryl, Cnaminoalkyl, Cnhaloalkyl, Cnheteroaryl, Cncycloalkyl, or Cnheterocycloalkyl, wherein Raof the B(ORa)2is H or an alkyl, wherein B of the B(ORa)2is boron, wherein n of the Cnis 1 — 10, wherein each of R2- R5are independently -H, -CN, -COOH, -COOMe, -CONH2, B(ORa)2, the acid isostere, the halo, -CONHOH, -NH-S02-C1-C6-alkyl, -NHS02Ar, the Cnalkyl, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, the Cnaryl, the Cnaminoalkyl, the Cnhaloalkyl, the Cnheteroaryl, the Cncycloalkyl, or the Cnheterocycloalkyl, wherein the Ar of - HS02Ar is selected from the group consisting of: phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3- benzoxadi azole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-l,4-benzoxazine, 1,5- naphthyridine, 1,8-naphthyridine, acridine, phenazine, and xanthene, wherein each of the Cnalkyl, the Cnalkenyl, the Cnalkynyl, the Cnaryl, the Cnaminoalkyl, the Cnhaloalkyl, the Cnheteroaryl, the Cncycloalkyl, or the Cnheterocycloalkyl is unsubstituted or substituted with a quantity of substituents being between 1-5, wherein each of the substituents is the same or different, wherein each of the substituents is selected from the group consisting of: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, and -Cq-U- Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, wherein the U of -Cq-U-Cqis any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, S02, or N(R1)(R1), wherein each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, the Cnaryl, the Cnaminoalkyl, the Cnhaloalkyl, the Cnheteroaryl, the Cncycloalkyl, or the Cnheterocycloalkyl, wherein each R1of N(R1)(R1) is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, wherein Q is a bond or O, wherein X is C, N, O, or S such that R6is not present if X is O or S, wherein X is C, N, O, or S, and wherein n is 0, 1, 2, or 3.

[0017] In some embodiments, the invention includes compounds of Formula II, wherein a heterocycloalkyl group is formed by bonding two of R7, R8, or R9to form:

[0018] Additional embodiments of the invention include compounds of Formula III or pharmaceutically acceptable salts or esters thereof: wherein R1is selected from the group consisting of: -CN, alkyl, -H, halo,2H, amino, alkoxy, aminoalkyl, (amino)alkoxy, alkenyl, alkynyl, alkoxy, hydroxy, alkylhydroxy, aryloxy, alkyl(aryl), (alkoxyalkyl)amino, aryl, aryl(halo), heteroaryl, hydroxyl-alkyl, hydroxyl-aryl, (aryl)alkyl, C(O)0H, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, and C(O)NH2, wherein each of R3and R4are independently -H, the halo, Cnalkyl, Cnalkyl, Cnalkenyl, Cnalkynyl, Cnaryl, Cnaminoalkyl, Cnhaloalkyl, Cnheteroaryl, Cncycloalkyl, Cnheterocycloalkyl, and -Cq-U-Cq, wherein n of Cnis 1 - 10, wherein each q of -Cq-U-Cqis independently 0 to 10, wherein the U of -Cq-U-Cqis any one of O, S, S02, or N(R1)(R1), wherein each R1of N(R1)(R1) are independently hydrogen, wherein each of the Cnalkyl, the Cnalkenyl, the Cnalkynyl, the Cnaryl, the Cnaminoalkyl, the Cnhaloalkyl, the Cnheteroaryl, the Cncycloalkyl, and the Cnheterocycloalkyl are unsubstituted or substituted with a quantity of substituents being between 1-5, wherein each of the substituents are the same or different, wherein each of the substituents is selected from the group consisting of: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, wherein R6is independently H or alkyl, wherein each of R7and R8are independently hydrogen,2H, fluoro or alkyl, wherein R6and R7are bonded with an adjoining R group to form a fused group, wherein the fused group is selected from the group consisting of: a fused cycloalkyl, a fused heterocycloalkyl, a fused aryl, and a fused heteroaryl ring, wherein the fused group comprises between 4 to 10 carbon atoms, wherein n of Formula III is 0 or 1, wherein Q is a bond or O, wherein X is C, N, O, or S such that R6is not present if X is O or S, and wherein Z1or W1are independently C, N, O, or S.

[0019] Another embodiment of the invention includes compounds of Formula III wherein X is N. An embodiment the invention includes compounds of Formula III wherein R6is hydrogen and X is N.

[0020] A further embodiment the invention includes compounds of Formula III wherein R3is alkyl and R1is cyano.

[0021] An additional embodiment the invention includes compounds of Formula III wherein X is N and n=0.

[0022] An embodiment the invention includes compounds of Formula III wherein X is N and n=l.

[0023] In general, the present invention succeeds in conferring the following benefits and objectives.

[0024] It is an object of the present invention to utilize the compound according to Formula (I), (II) or (III) or a pharmaceutically acceptable salt or ester thereof to treat disorders acting on the fatty acid binding protein (FABP4). It is an object of the present invention to provide a pharmaceutical composition comprising a compound according to Formula (I), (II) or (III) as an active ingredient, in combination with a pharmaceutically acceptable diluent or carrier, for use in the treatment of disorders acting on the FABP4. Here, the pharmaceutical composition can further comprise an additional therapeutically active agent.

[0025] It is an object of the present invention to provide a method for the treatment of disorders acting on the FABP4. Such method comprises numerous process steps, such as: administering an effective amount of a compound according to Formula (I), (II) or (III) to a subject in need of such treatment (preferably, a human). The method optionally includes a process step regarding co-administration with other therapeutic agents, either as a single (or multiple) dosing, and either simultaneously or sequentially.

[0026] It is an object of the present invention to provide a method for inhibiting FABP4, which comprises a process step of administering an effective amount of a compound according to Formula (I), (II) or (III) to a subject in need of such treatment (preferably, a human).

[0027] It is an object of the present invention to provide a method to use a compound according to Formula (I), (II) or (III) for the manufacture of a medicament for use in the treatment of disorders acting on the FABP4. Examples of such disorders include type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, atherosclerosis, intracranial atherosclerotic disease, non-alcoholic steatohepatitis, asthma, multiple sclerosis, Alzheimer’s disease, other chronic inflammatory and autoimmune / inflammatory diseases, chronic heart disease, polycystic ovary syndrome, preeclampsia, and cancer.

[0028] Other features and advantages of the invention will be apparent from the detailed description and the claims.

[0029] Description of the Preferred Embodiments

[0030] Reference will now be made in detail to each embodiment of the present invention. Such embodiments are provided by way of explanation of the present invention, which is not intended to be limited thereto. In fact, those of ordinary skill in the art may appreciate upon reading the present specification and viewing the present drawings that various modifications and variations can be. Definitions

[0031] As used herein, the term “acid isostere” includes, but is not limited to, the following functional groups, where R is H or alkyl. The term “alkyl” refers to a saturated, straight-chain hydrocarbon group, or branched- chain hydrocarbon group having from 1 to 20 carbon atoms. Representative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, 2-methyl- 1 -propyl, 2-methyl-2-propyl,

[0032] 2-methyl- 1 -butyl, 3 -methyl- 1 -butyl, 2-m ethyl-3 -butyl, 2,2-dimethyl- 1 -propyl, 2-methyl- 1 -pentyl,

[0033] 3 -methyl- 1 -pentyl, 4-methyl- 1 -pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl- 1 -butyl, 3,3-dimethyl-l-butyl, 2-ethyl- 1 -butyl, butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and the like, and longer alkyl groups, such as heptyl, octyl, and the like. Moreover, the number of carbons on an alkyl chain can be defined in association with the C atom such as C1-10, where C1-10is a carbon chain having 1 to 10 carbon atoms.

[0034] The term “alkoxy” as used herein refers to an alkyl group singularly bonded to oxygen and includes -O-(alkyl), wherein alkyl is defined above.

[0035] The term “amino” as used herein refers to an -NH2group.

[0036] The term “alkenyl” refers to a hydrocarbon group formed when a hydrogen atom is removed from an alkene group. Alkenyl compounds are named by replacing the -e from the parent alkene's name with -yl. An example includes H2C=CH- (e.g., ethenyl or vinyl).

[0037] The term “alkynyl” refers to a fragment containing an open point of attachment on a carbon atom, that would form if a hydrogen atom bonded to a triply bonded carbon is removed from the molecule of an alkyne.

[0038] The term “haloalkyl” refers to any alkyl radical having one or more hydrogen atoms replaced by a halogen atom.

[0039] The term “phenyl” refers to a univalent hydrocarbon radical (C6H5) formally derived from benzene by the removal of a hydrogen atom.

[0040] The term “naphthyl” refers to an isomeric univalent radical formally derived from naphthalene by removal of a hydrogen atom.

[0041] The term “pyrrole” refers to a heterocyclic aromatic organic compound that is a five- membered ring with the formula C4H4NH.

[0042] The term “imidazole” refers to an organic compound with the formula C3N2H4.

[0043] The term “thiophene” refers to a heterocyclic compound with the formula C4H4S.

[0044] The term “furan” refers to a heterocyclic organic compound consisting of a five- membered aromatic ring with four carbon atoms and one oxygen.

[0045] The term “thiazole” refers to a heterocyclic compound that contains both sulfur and nitrogen and contains the molecular formula C3H3NS.

[0046] The term “isothiazole” or 1,2-thiazole refers to an organic compound containing a five- membered aromatic ring that consists of three carbon atoms, one nitrogen atom, and one sulfur atom.

[0047] The term “thiadiazole” refers to a sub-family of azole compounds, that are five- membered heterocyclic compounds containing one sulfur and two nitrogen atoms. The term “oxazole” refers to the parent compound for a class of heterocyclic aromatic organic compounds. Oxazoles are azoles with an oxygen and a nitrogen separated by one carbon.

[0048] The term “isoxazole” refers to an azole with an oxygen atom next to the nitrogen.

[0049] The term “oxadiazole” refers to a class of heterocyclic aromatic chemical compounds of the azole family with the molecular formula C2H2N2O.

[0050] The term “pyridine” refers to a basic heterocyclic organic compound with the chemical formula C5H5N. Pyridine is structurally related to benzene, with one methine group replaced by a nitrogen atom.

[0051] The term “pyrazine” refers to a heterocyclic organic compound with the chemical formula C4H4N2. Pyrazine is less basic than pyridine, pyridazine and pyrimidine.

[0052] The term “pyrimidine” refers to a heterocyclic organic compound similar to pyridine.

[0053] One of the three diazines, pyrimidine has the nitrogen atoms at positions 1 and 3 in the ring.

[0054] The term “pyridazine” is a heterocyclic organic compound with the molecular formula (CH)4N2.Pyrimidine contains a six-membered ring with two adjacent nitrogen atoms.

[0055] The term “pyrazole” refers to an organic compound with the formula C3H3N2H. Pyrazole is a heterocycle characterized by a 5-membered ring of three carbon atoms and two adjacent nitrogen atoms.

[0056] The term “trizole” refers to any of the heterocyclic compounds with molecular formula C2H3N3, having a five-membered ring of two carbon atoms and three nitrogen atoms.

[0057] The term “tetrazole” refers to a class of synthetic organic heterocyclic compounds, consisting of a 5-member ring of four nitrogen atoms and one carbon atom. The name tetrazole also refers to the parent compound with formula CH2N4.

[0058] The term “chroman” or “chromane” refers to a heterocyclic chemical compound with the chemical formula C9H10O.

[0059] The term “quinoline” refers to a heterocyclic organic compound with the chemical formula C9H7N.

[0060] The term “quinoxaline” or “benzopyrazine” refers to a heterocyclic compound containing a ring complex made up of a benzene ring and a pyrazine ring.

[0061] The term “isoquinoline” refers to a heterocyclic aromatic organic compound.

[0062] Isoquinoline is a structural isomer of quinoline. Isoquinoline and quinoline are benzopyridines, which are composed of a benzene ring fused to a pyridine ring. The term “phthalazine,” “benzo-orthodiazine,” or “benzopyridazine” is a heterocyclic organic compound with the molecular formula C8H6N2. It is isomeric with other naphthyridines, including quinoxaline, cinnoline and quinazoline.

[0063] The term “cinnoline” is a heterocyclic compound with the formula C8H6N2. It is isomeric with other naphthyridines, including quinoxaline, phthalazine and quinazoline.

[0064] The term “quinazoline” refers to an organic compound with the formula C8H6N2. Quinazoline is a heterocycle with a bicyclic structure consisting of two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.

[0065] The term “indole” is a heterocyclic organic compound with formula C8H7N. Indole has a bicyclic structure, consisting of a six-membered benzene ring fused to a five-membered pyrrole ring.

[0066] The term “isoindole” is a benzo-fused pyrrole and is an isomer of indole.

[0067] The term “indoline” is a heterocyclic organic compound with the chemical formula C8H9N. Indoline has a bicyclic structure, consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing ring.

[0068] The term “isoindoline” refers to a heterocyclic organic compound with the molecular formula C8H9N. The parent compound has a bicyclic structure, consisting of a six-membered benzene ring fused to a five-membered nitrogen-containing ring.

[0069] The term “benzothiophene” refers to an organic compound with a molecular formula

[0070] C8H6S.

[0071] The term “benzofuran” refers to a heterocyclic compound consisting of fused benzene and furan rings.

[0072] The term “isobenzofuran” refers to a heterocyclic compound consisting of fused benzene and furan rings. Isobenzofuran is isomeric with benzofuran.

[0073] The term “benzoxazole” refers to an organic compound with a molecular formula C7H5NO and includes a benzene-fused oxazole ring structure.

[0074] The term “benzothi azole” refers to a heterocyclic compound with the chemical formula C7H5NS.

[0075] The term “benzimidazole” refers to a heterocyclic organic compound. Benzimidazole is a bicyclic compound that consists of the fusion of benzene and imidazole. The term “indazole” or “isoindazole” refers to a heterocyclic organic compound that consists of the fusion of benzene and pyrazole.

[0076] The term “benzodioxane” refers to isomeric chemical compounds with the molecular formula C8H8O2.

[0077] The term “indane” or “indan” refers to an organic compound with the formula C6H4(CH2)3

[0078] The term “acridine” refers to an organic compound and a nitrogen heterocycle with the formula C13H9N. Acridines are substituted derivatives of the parent ring. It is a planar molecule that is structurally related to anthracene with one of the central CH groups replaced by nitrogen.

[0079] The term “phenazine” refers to an organic compound with the formula (C6H4)2N2. Phenazine is a dibenzo annulated pyrazine.

[0080] The term “xanthene” refers to an organic compound with the formula CH2[C6H4]2O.

[0081] The term “isochroman” refers to a compound having the formula C9H10O and the following structure:

[0082] The term “2,1,3-benzoxadiazole” refers to an organic compound having the following structure:

[0083] The term “2,1,3-benzothiazole” refers to a heterocyclic compound with the chemical formula C7H5NS.

[0084] The term “2,1,3-benzoselenadiazole” refers to an organic compound having the following structure:

[0085] The term “tetrahydroquinoline” refers to an organic compound that is the semi- hydrogenated derivative of quinoline.

[0086] The term “3,4-dihydro-2H-l,4-benzoxazine” refers to an organic compound having the following structure:

[0087] The term “1,5- naphthyridine” refers to an organic compound having the following structure:

[0088] The term “1,8-naphthyridine” refers to an organic compound with the formula C8H6N2.

[0089] The term “aryl” means a monocyclic, bicyclic, or tricyclic aromatic group, wherein all rings of the group are aromatic and all ring atoms are carbon atoms. For bicyclic or tricyclic systems, the individual aromatic rings are fused to one another. Examples of aryl groups are 6 and 10 membered aryls. Further examples of aryl groups include, but are not limited to, phenyl, naphthalene, and anthracene.

[0090] The term “cyano” as used herein means a substituent having a carbon atom joined to a nitrogen atom by a triple bond.

[0091] The term “deuterium” as used herein means a stable isotope of hydrogen having one proton and one neutron.

[0092] The term “halogen” as used herein refers to fluorine, chlorine, bromine, iodine, astatine, or tennessine. The term “halo” represents a group comprising a halogen.

[0093] The term “hydroxy” means an -OH group.

[0094] The term “oxo” means an =O group and may be attached to a carbon atom or a sulfur atom.

[0095] The term “N-oxide” refers to the oxidized form of a nitrogen atom.

[0096] The term “cycloalkyl” refers to a saturated or partially saturated, monocyclic, fused polycyclic, bridged polycyclic, or spiro polycyclic carbocycle having from 3 to 15 carbon ring atoms. A non-limiting category of cycloalkyl groups are saturated or partially saturated, monocyclic carbocycles having from 3 to 6 carbon atoms. Illustrative examples of cycloalkyl groups include, but are not limited to, the following moieties:

[0097] The term "heterocycloalkyl" as used herein refers to a monocyclic, or fused, bridged, or spiro polycyclic ring structure that is saturated or partially saturated and has from three to 12 ring atoms selected from carbon atoms and up to three heteroatoms selected from nitrogen, oxygen, and sulfur. The ring structure may optionally contain up to two oxo groups on carbon or sulfur ring members, or an N-oxide. Illustrative heterocycloalkyl entities include, but are not limited to the following:

[0098] The term “heteroaryl” refers to a monocyclic, or fused polycyclic, aromatic heterocycle having from three to 15 ring atoms that are selected from carbon, oxygen, nitrogen, and sulfur. Suitable heteroaryl groups do not include ring systems that must be charged to be aromatic, such as pyrylium. Suitable 5-membered heteroaryl rings (as a monocyclic heteroaryl or as part of a polycyclic heteroaryl) have one oxygen, sulfur, or nitrogen ring atom, or one nitrogen plus one oxygen or sulfur, or 2, 3, or 4 nitrogen ring atoms. Suitable 6-membered heteroaryl rings (as a monocyclic heteroaryl or as part of a polycyclic heteroaryl) have 1, 2, or 3 nitrogen ring atoms. Examples of heteroaryl groups include, but are not limited to, pyridinyl, imidazolyl, imidazopyridinyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl.

[0099] The term “fused heteroaryl” refers to a heteroaryl as defined above, having two constituent aromatic rings, wherein the two rings are fused to one another and at least one of the rings is a heteroaryl as defined above. Fused heteroaryls include fused heteroaryl groups comprising 1, 2, 3, or 4 heteroatom ring atoms selected from O, N or S. In certain embodiments, wherein the heteroatom is N it can be an N-oxide. Fused heteroaryls also include 8-, 9-, or 10- membered fused heteroaryl groups. Fused heteroaryls also include 8-, 9-, or 10-membered fused heteroaryl groups that have 1, 2, 3, or 4 heteroatom ring atoms selected from O, N or S. Illustrative examples of fused heteroaryls include, but are not limited to, the following:

[0100] Those skilled in the art will recognize that the species of heteroaryl, cycloalkyl, and heterocycloalkyl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected. As used herein, “liquid chromatography-mass spectrometry” or LC-MS is an analytical chemistry technique that combines the physical separation capabilities of liquid chromatography (or HPLC) with the mass analysis capabilities of mass spectrometry (MS).

[0101] As used herein, “proton nuclear magnetic resonance” or 1H NMR is the application of nuclear magnetic resonance in NMR spectroscopy with respect to hydrogen- 1 nuclei within the molecules of a substance, in order to determine the structure of its molecules.

[0102] As used herein, the term “substituted” means that the specified group or moiety bears one or more suitable substituents. As used herein, the term “unsubstituted” means that the specified group bears no substituents. As used herein, the term “optionally substituted” means that the specified group is unsubstituted or substituted by the specified number of substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.

[0103] The term “substituent” refers to an atom or group of atoms that replaces one or more hydrogen atoms on the parent chain of a hydrocarbon, becoming a moiety of the resultant new molecule.

[0104] Any atom that is represented herein with an unsatisfied valence is assumed to have the sufficient number of hydrogen atoms to satisfy the atom’s valence.

[0105] When any variable (e.g., alkyl, Ra, R1, etc.) appears in more than one place in any formula or description provided herein, the definition of that variable on each occurrence is independent of its definition at every other occurrence.

[0106] Numerical ranges, as used herein, are intended to include sequential whole numbers. For example, a range expressed as “from 0 to 4” or “0-4” includes 0, 1, 2, 3 and 4.

[0107] When a multifunctional moiety is shown, the point of attachment to the remainder of the formula can be at any point on the multifunctional moiety. In some embodiments, the point of attachment is indicated by a line or hyphen. For example, aryloxy- refers to a moiety in which an oxygen atom is the point of attachment to the core molecule while aryl is attached to the oxygen atom.

[0108] As used herein, the term “subject” encompasses mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the Mammalian class, such as: humans, non-human primates (e.g., chimpanzees, apes, and monkey species), farm animals (e.g., cattle, horses, sheep, goats, swine, etc.), domestic animals (e.g., rabbits, dogs, cats, etc.), and laboratory animals (e.g., rodents, such as rats, mice and guinea pigs, and the like). Examples of non-mammals include, but are not limited to, birds, fish, and the like. In one embodiment of the present invention, the mammal is a human.

[0109] The term “patient” or “subject” includes both human and animals.

[0110] The terms “effective amount” or “therapeutically effective amount” refer to a sufficient amount of the agent to provide the desired biological result. That result can be reduction and / or alleviation of the signs, symptoms, or causes of a disease or medical condition, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic use is the amount of a compound, or of a composition comprising the compound, that is required to provide a clinically relevant change in a disease state, symptom, or medical condition. An appropriate “effective” amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation. Thus, the expression “effective amount” generally refers to the quantity for which the active substance has a therapeutically desired effect.

[0111] As used herein, the terms “treat” or “treatment” encompass both “preventative” and “curative” treatment. As used herein, the phrase “preventative treatment” is meant to indicate a postponement of development of a disease, a symptom of a disease, or medical condition, suppressing symptoms that may appear, or reducing the risk of developing or recurrence of a disease or symptom. As used herein, the phrase “curative treatment” refers to reducing the severity of or suppressing the worsening of an existing disease, symptom, or condition. Thus, “treatment” includes ameliorating or preventing the worsening of existing disease symptoms, preventing additional symptoms from occurring, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping the symptoms of the disease or disorder.

[0112] Specific Embodiments

[0113] Formula I

[0114] The present invention, in one of its embodiments, relates to a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof:

[0115] wherein each of R1and R6-R9are independently -H, -CN, -COOH, -CONH2, B(ORa)2, an acid isostere, a halo, Cnalkyl, Cnalkenyl, Cnalkynyl, Cnaryl, Cnaminoalkyl, Cnhaloalkyl, Cnheteroaryl, Cncycloalkyl, or Cnheterocycloalkyl, wherein Raof the B(ORa)2is H or an alkyl, wherein B of the B(ORa)2is boron, wherein n of Cnis 1 - 10, wherein each of R2- R5are independently -H, -CN, -COOH, -COOMe, -CONH2, B(ORa)2, the acid isostere, the halo, -CONHOH, -NH-S02-C1-C6-alkyl, -NHS02Ar, the Cnalkyl, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, the Cnaryl, the Cnaminoalkyl, the Cnhaloalkyl, the Cnheteroaryl, the Cncycloalkyl, or the Cnheterocycloalkyl, wherein the Ar of - HS02Ar is selected from the group consisting of: phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3- benzoxadi azole, benzothiazole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-l,4-benzoxazine, 1,5- naphthyridine, 1,8-naphthyridine, acridine, phenazine, and xanthene, wherein each of the Cnalkyl, the Cnalkenyl, the Cnalkynyl, the Cnaryl, the Cnaminoalkyl, the Cnhaloalkyl, the Cnheteroaryl, the Cncycloalkyl, and the Cnheterocycloalkyl are unsubstituted or substituted with a quantity of substituents being between 1-5, wherein each of the substituents is the same or different, wherein each of the substituents is selected from the group consisting of: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, and -Cq-U- Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, wherein the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, S02, and N(R1)(R1), wherein each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each R1of N(R1)(R1) is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, wherein Q is a bond or O, wherein X is C, N, O, or S such that R6is not present if X is O or S, wherein “A” is a saturated or unsaturated ring depicted by wherein Y, T, W, and Z are independently a bond, C, N, O, an alkyl having 1 to 4 carbon atoms or an alkenyl having 1 to 4 carbon atoms, and wherein n is 0, 1, 2, or 3.

[0116] In one embodiment, the invention comprises the compound of Formula I where at least one of R1and R2are bonded forming a fused heteroaryl.

[0117] In one embodiment, the invention comprises the compound of Formula I where at least one of R2and R3are bonded forming a fused heteroaryl. In one embodiment, the invention comprises the compound of Formula I where at least one of R3and R4are bonded forming a fused heteroaryl.

[0118] In one embodiment, the invention comprises the compound of Formula I where at least one of R4and R5are bonded forming a fused heteroaryl.

[0119] In one embodiment, the invention comprises the compound of Formula I where at least one of R5and R6are bonded forming a fused heteroaryl.

[0120] In one embodiment, the invention comprises the compound of Formula I where at least one of R6and R7are bonded forming a fused heteroaryl.

[0121] In one embodiment, the invention comprises the compound of Formula I where at least one of R7and R8are bonded forming a fused heteroaryl.

[0122] In one embodiment, the invention comprises the compound of Formula I where at least one of R8and R9are bonded forming a fused heteroaryl.

[0123] In one embodiment, the invention comprises the compound of Formula I where at least one of R1and R2are bonded forming a fused heterocycloalkyl.

[0124] In one embodiment, the invention comprises the compound of Formula I where at least one of R2and R3are bonded forming a fused heterocycloalkyl.

[0125] In one embodiment, the invention comprises the compound of Formula I where at least one of R3and R4are bonded forming a fused heterocycloalkyl.

[0126] In one embodiment, the invention comprises the compound of Formula I where at least one of R4and R5are bonded forming a fused heterocycloalkyl.

[0127] In one embodiment, the invention comprises the compound of Formula I where at least one of R5and R6are bonded forming a fused heterocycloalkyl.

[0128] In one embodiment, the invention comprises the compound of Formula I where at least one of R6and R7are bonded forming a fused heterocycloalkyl.

[0129] In one embodiment, the invention comprises the compound of Formula I where at least one of R7and R8are bonded forming a fused heterocycloalkyl.

[0130] In one embodiment, the invention comprises the compound of Formula I where at least one of R8and R9are bonded forming a fused heterocycloalkyl.

[0131] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, and where R3-R9, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is -H, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0132] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is -CN, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0133] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is -COOH, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0134] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is -CONH2, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0135] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is B(ORa)2, where B of B(ORa)2is boron, where Ra of B(ORa)2is H, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0136] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is B(ORa)2, where B of B(ORa)2is boron, where Raof B(ORa)2is an alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0137] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is an acid isostere as disclosed herein, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0138] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a halo, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0139] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl, where n of the Cnalkyl is 1 - 10, where the Cnalkyl is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0140] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl, where n of the Cnalkyl is 1 - 10, where the Cnalkyl is substituted with 1 substituent, where the substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T,

[0141] Y, Z, Q and X are as defined.

[0142] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl, where n of the Cnalkyl is 1 - 10, where the Cnalkyl is substituted with 2-5 substituents, where the substituents are the same, and where each of the substituents is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0143] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl, where n of the Cnalkyl is 1 - 10, where the Cnalkyl is substituted with 2-5 substituents, where the substituents differ, where each of the substituents is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1, where the substituent is H, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0144] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is2H, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0145] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is a halo, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0146] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an amino group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0147] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an alkoxy group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0148] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is a cyano group, and where R2- R5, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an aminoalkyl-, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0149] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an (amino)alkoxy-, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0150] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an -alkyl group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0151] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an -alkenyl group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0152] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an -alkynyl group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0153] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an alkoxy- group, and where R2- R5, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is a hydroxy group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0154] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an -alkylhydroxy group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0155] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an aryloxy- group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0156] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an -alkyl(aryl) group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0157] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an (alkoxyalkyl)amino- group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0158] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an aryl group, and where R2- R5, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an -aryl(halo) group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0159] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is a -heteroaryl group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0160] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is a hydroxyl-alkyl- group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0161] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is a hydroxyl-aryl- group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0162] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is an (aryl)alkyl- group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0163] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is a -S(O)2-alkyl group, and where R2- R5, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is a -S(O)2-aryl group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0164] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is a -C(O)alkyl group, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0165] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis aryl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0166] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis heteroaryl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0167] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where the n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis cycloalkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0168] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis heterocycloalkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0169] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis O, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0170] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis S, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0171] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis SO2, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0172] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0173] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently the Cnalkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0174] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently the Cnalkenyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0175] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently the Cnalkynyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0176] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U- Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently the Cnaryl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0177] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently the Cnaminoalkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0178] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently the Cnhaloalkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0179] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently the Cnheteroaryl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0180] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently the Cncycloalkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0181] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently the Cnheterocycloalkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0182] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of the Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0183] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with one substituent, where the substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T,

[0184] Y, Z, Q and X are as defined.

[0185] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents, where each substituent is the same, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0186] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnis 1 - 10, where a quantity of the substituents is 1, where the substituent is -Cq-U-Cq, where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents, where each substituent differs, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0187] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where each of the substituents are the same, where each of the substituents are H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0188] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where each of the substituents are different, where each of the substituents are H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0189] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where each of the substituents are the same, where each of the substituents are H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, or -Cq-U-Cq, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0190] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where each of the substituents are different, where each of the substituents are H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, or -Cq-U-Cq, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0191] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -Cq-U-Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0192] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -Cq-U-Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis aryl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0193] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -Cq-U-Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis heteroaryl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0194] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -Cq-U-Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis cycloalkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0195] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -Cq-U-Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis heterocycloalkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0196] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -Cq-U-Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis O, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0197] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -Cq-U-Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis S, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0198] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -Cq-U-Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis SO2, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0199] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -Cq-U-Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), wherein each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0200] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -Cq-U-Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), wherein each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0201] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -Cq-U-Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), wherein each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, each R1of N(R1)(R1) is substituted with 1-5 substituents, where each substituent is the same, where each substituent is: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0202] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n is 1 - 10, where a quantity of the substituents is 2-5, where at least one of the substituents is -Cq-U-Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), wherein each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cn alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, each R1of N(R1)(R1) is substituted with 1-5 substituents, where each substituent differs, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0203] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0204] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, where the Cnalkenyl is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0205] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0206] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of -Cq- U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of -Cq- U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0207] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of -Cq- U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0208] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of -Cq- U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0209] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or - C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0210] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or - C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0211] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0212] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T,

[0213] Y, Z, Q and X are as defined.

[0214] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl- , (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0215] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0216] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, where the Cnalkenyl is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0217] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0218] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of -Cq- U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0219] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of -Cq- U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0220] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of -Cq- U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0221] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of -Cq- U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0222] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or - C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0223] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or - C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0224] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0225] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0226] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T,

[0227] Y, Z, Q and X are as defined.

[0228] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl- , (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0229] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0230] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0231] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0232] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0233] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, - alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, - aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2- aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0234] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1ofN(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0235] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq.where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0236] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or - C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0237] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0238] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0239] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0240] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T,

[0241] Y, Z, Q and X are as defined.

[0242] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq.where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl- , (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0243] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl, where n of Cnis 1 - 10, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0244] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0245] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0246] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0247] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, - alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, - aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2- aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0248] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq.where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0249] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or - C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0250] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0251] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq.where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0252] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0253] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T,

[0254] Y, Z, Q and X are as defined.

[0255] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq.where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl- , (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0256] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroalkyl, where n of Cnis 1 - 10, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0257] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0258] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, - alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0259] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, - alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, - aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2- aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0260] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0261] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0262] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0263] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0264] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq- U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0265] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq- U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0266] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq- U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T,

[0267] Y, Z, Q and X are as defined.

[0268] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq- U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T,

[0269] Y, Z, Q and X are as defined.

[0270] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl where n of Cnis 1 - 10, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0271] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0272] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0273] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq.where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0274] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, - alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, - aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2- aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0275] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0276] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq,where each q of - Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0277] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or - C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0278] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0279] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0280] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0281] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T,

[0282] Y, Z, Q and X are as defined.

[0283] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl- , (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0284] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheterocycloalkyl where n of Cnis 1 - 10, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0285] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoaryl, where n of Cnis 1 - 10, where the Cnalkenyl is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0286] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheterocycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0287] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheterocycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq.where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0288] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheterocycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq.where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, - alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, - aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2- aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0289] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheterocycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq.where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0290] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheterocycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 1 substituent, where the substituent is -Cq-U-Cq.where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1ofN(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0291] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheterocycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheterocycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where the substituents differ and are independently: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0292] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheterocycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0293] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheterocycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1 substituent comprising: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheterocycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that are the same and include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T,

[0294] Y, Z, Q and X are as defined.

[0295] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl, where n of Cnis 1 - 10, where the Cnalkenyl is substituted with 2-5 substituents, where at least one of the substituents is -Cq-U-Cq,where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 2-5 substituents that differ and may include: H,2H, halo, amino, alkoxy, cyano, aminoalkyl- , (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, W, T, Y, Z, Q and X are as defined.

[0296] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, each of R2- R5are independently -H, -CN, -COOH, -COOMe, -CONH2, B(ORa)2, the acid isostere, the halo, -CONHOH, -NH-SO2-C1-C6-alkyl, -NHSO2Ar, the Cnalkyl, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, the Cnaryl, the Cnaminoalkyl, the Cnhaloalkyl, the Cnheteroaryl, the Cncycloalkyl, or the Cnheterocycloalkyl, where the B of B(ORa)2 is Boron, where the Raof B(ORa)2is H or alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0297] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where the Ar of -NHSO2Ar is selected from the group consisting of: phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothi azole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-l,4-benzoxazine, 1,5- naphthyridine, 1,8- naphthyridine, acridine, phenazine, and xanthene, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0298] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is naphthyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0299] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is pyrrole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0300] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is imidazole, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0301] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is thiophene, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isothiazole, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0302] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is thiadiazole, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0303] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is oxazole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0304] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isoxazole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0305] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is oxadiazole, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0306] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is pyridine, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0307] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is pyrazine, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0308] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is pyrimidine, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0309] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is pyridazine, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0310] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is pyrazole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0311] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is triazole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0312] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is tetrazole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0313] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is chroman, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0314] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isochroman, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0315] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is quinoline, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is quinoxaline, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0316] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isoquinoline, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0317] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is phthalazine, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0318] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is cinnoline, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0319] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is quinazoline, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0320] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is indole, and where R1, R6-R9,

[0321] W, T, Y, Z, Q and X are as defined.

[0322] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isoindole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0323] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is indoline, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0324] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isoindoline, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0325] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is benzothiophene, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0326] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is benzofuran, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0327] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isobenzofuran, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0328] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is benzoxazole, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0329] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 2,1,3-benzoxadiazole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0330] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is benzothi azole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 2,1,3-benzothiazole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0331] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 2,1,3-benzoselenadiazole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0332] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is benzimidazole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0333] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is indazole, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0334] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is benzodioxane, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0335] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is indane, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0336] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 1,2,3,4-tetrahydroquinoline, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0337] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 3,4-dihydro-2H-l,4- benzoxazine, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0338] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 1,5- naphthyridine, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0339] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 1,8-naphthyridine, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0340] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is acridine, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0341] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is phenazine, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0342] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is xanthene, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0343] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is Cnalkenyl, Cnalkynyl, Cnaryl, Cnaminoalkyl, Cnhaloalkyl, Cnheteroaryl, Cncycloalkyl, or Cnheterocycloalkyl that is unsubstituted, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0344] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is Cnalkenyl, Cnalkynyl, Cnaryl, Cnaminoalkyl, Cnhaloalkyl, Cnheteroaryl, Cncycloalkyl, or Cnheterocycloalkyl that is substituted with 1 substituent, where n of Cnis 1 - 10, where the substituent is: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, or -Cq-U-Cq,and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0345] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is Cnalkenyl, Cnalkynyl, Cnaryl, Cnaminoalkyl, Cnhaloalkyl, Cnheteroaryl, Cncycloalkyl, or Cnheterocycloalkyl that is substituted with 1 substituent, where n of Cnis 1 - 10, where the substituent is -Cq-U-Cq.where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis one of: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, and N(R1)(R1), and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0346] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is Cnalkenyl, Cnalkynyl, Cnaryl, Cnaminoalkyl, Cnhaloalkyl, Cnheteroaryl, Cncycloalkyl, or Cnheterocycloalkyl that is substituted with 1 substituent, where n of Cnis 1 - 10, where the substituent is -Cq-U-Cq.where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0347] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is Cnalkenyl, Cnalkynyl, Cnaryl, Cnaminoalkyl, Cnhaloalkyl, Cnheteroaryl, Cncycloalkyl, or Cnheterocycloalkyl that is substituted with 1 substituent, where n of Cnis 1 - 10, where the substituent is -Cq-U-Cq.where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents that are the same, where the substituents are H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0348] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is Cnalkenyl, Cnalkynyl, Cnaryl, Cnaminoalkyl, Cnhaloalkyl, Cnheteroaryl, Cncycloalkyl, or Cnheterocycloalkyl that is substituted with 1 substituent, where n of Cnis 1 - 10, where the substituent is -Cq-U-Cq.where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents that differ, where each of the 1-5 substituents are H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0349] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is substituted, where the quantity of substituents is 1, where the substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, where n of Cnis 1 - 10, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0350] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is substituted, where the quantity of substituents is 2-5, where each of the substituents is the same and is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0351] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is substituted, where the quantity of substituents is 2-5, where each of the substituents differs and is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0352] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is substituted, where the quantity of substituents is 1, where the substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0353] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is substituted, where the quantity of substituents is 1, where the substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0354] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is substituted, where n of Cnis 1 - 10, where the quantity of substituents is 1, where the substituent is -Cq-U-Cq,, where each q of -Cq- U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is substituted, where n of Cnis 1 - 10, where the quantity of substituents is 1, where the substituent is -Cq-U-Cq,, where each q of -Cq- U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where each of the 1-5 substituents is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0355] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkenyl that is unsubstituted, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0356] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkenyl that is substituted with 1-5 substituents, where n of Cnis 1 - 10, where each of the substituents are the same or different and include H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0357] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkenyl that is substituted, where n of Cnis 1 - 10, where the quantity of substituents is 2-5, where each at least one of the substituents is -Cq-U- Cq., where each q of -Cq-U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0358] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkynyl, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0359] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkynyl that is unsubstituted, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0360] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkynyl that is substituted with 1-5 substituents that are the same or are different, where n of Cnis 1 - 10, where the substituent(s) is / are H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0361] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkynyl that is substituted, where n of Cnis 1 - 10, where the quantity of substituents is 1-5, where the substituent(s) is / are -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0362] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaryl, where n of Cnis 1 - 10, and where R1, R6- R9, W, T, Y, Z, Q and X are as defined.

[0363] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaryl that is unsubstituted, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0364] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaryl that is substituted, where n of Cnis 1 - 10, where the quantity of substituents is 1-5, where the substituent(s) are the same or are different, where each of the substituent(s) is / are: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, or -Cq-U-Cq, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0365] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaryl that is substituted, where n of Cnis 1 - 10, where the quantity of substituents is 1-5, where at least one the substituents is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0366] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaminoalkyl, where n of the Cnis 1 — 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0367] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaminoalkyl that is unsubstituted, where n of the Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0368] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaminoalkyl that is substituted with 1-5 substituents, where n of the Cnis 1 — 10, where each of the substituents is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, - alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, or -Cq-U-Cq, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0369] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaminoalkyl that is substituted, where n of the Cnis 1 - 10, where the quantity of substituents is 1-5, where at least one of the substituents is -Cq- U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0370] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnhaloalkyl, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0371] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnhaloalkyl that is unsubstituted, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0372] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnhaloalkyl that is substituted with 1-5 substituents, where n of Cnis 1 - 10, where each of the substituents is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -Cq-U-Cq, or -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0373] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnhaloalkyl that is substituted, where n of Cnis 1 - 10, where the quantity of substituents is 1-5, where at least one of the substituents is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, - alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheteroaryl, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0374] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheteroaryl that is unsubstituted, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0375] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheteroaryl that is substituted with 1-5 substituents, where n of Cnis 1 - 10, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, or -Cq-U-Cq, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0376] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheteroaryl that is substituted, where n of Cnis 1 - 10, where the quantity of substituents is 1-5, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0377] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cncycloalkyl, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0378] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cncycloalkyl that is unsubstituted, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0379] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cncycloalkyl that is substituted with 1-5 substituents, where n of Cnis 1 - 10, where each of the substituents is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, - alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0380] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cncycloalkyl that is substituted, where n of Cnis 1 - 10, where at least one substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, - alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, - aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2- aryl, and -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0381] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheterocycloalkyl, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheterocycloalkyl that is unsubstituted, where n of Cnis 1 - 10, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0382] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheterocycloalkyl that is substituted with 1-5 substituents, where n of Cnis 1 - 10, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, or -Cq-U-Cq, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0383] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheterocycloalkyl that is substituted with 1-5 substituents, where n of Cnis 1 - 10, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, and where R1, R6-R9, W, T, Y, Z, Q and X are as defined.

[0384] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Q is a bond, and where R1- R9, W, T, Y, Z, and X are as defined.

[0385] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Q is O, and where R1- R9, W, T, Y, Z, and X are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is C, and where R1- R9, W, T, Y, Z, and Q are as defined.

[0386] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is N, and where R1- R9, W, T, Y, Z, and Q are as defined.

[0387] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is O, R6is not present, and where R1- R5, R7- R9, W, T, Y, Z, and Q are as defined.

[0388] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is S, R6is not present, and where R1- R5, R7- R9, W, T, Y, Z, and Q are as defined.

[0389] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where A is unsaturated, and where R1- R9, W, T, Y, Z, X, and Q are as defined.

[0390] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where A is saturated, and where R1- R9, W, T, Y, Z, X, and Q are as defined.

[0391] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Y is a bond, and where R1- R9, W, T, Z, X, and Q are as defined.

[0392] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Y is a C, and where R1- R9, W, T, Z, X, and Q are as defined.

[0393] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Y is a N, and where R1- R9, W, T, Z, X, and Q are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Y is a O, and where R1- R9, W, T, Z, X, and Q are as defined.

[0394] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Y is a an alkyl having 1 to 4 carbon atoms, and where R1- R9, W, T, Z, X, and Q are as defined.

[0395] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Y is a an alkenyl having 1 to 4 carbon atoms, and where R1- R9, W, T, Z, X, and Q are as defined.

[0396] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 - 3, and where R1- R9, W, T, Z, Y, X, and Q are as defined.

[0397] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where T is a bond, and where R1- R9, W, Y, Z, X, and Q are as defined.

[0398] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where T is a C, and where R1- R9, W, Y, Z, X, and Q are as defined.

[0399] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where T is a N, and where R1- R9, W, Y, Z, X, and Q are as defined.

[0400] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where T is a O, and where R1- R9, W, Y, Z, X, and Q are as defined.

[0401] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where T is a an alkyl having 1 to 4 carbon atoms, and where R1- R9, W, Y, Z, X, and Q are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where T is a an alkenyl having 1 to 4 carbon atoms, and where R1- R9, W, Y, Z, X, and Q are as defined.

[0402] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where W is a bond, and where R1- R9, Y, T, Z, X, and Q are as defined.

[0403] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where W is a C, and where R1- R9, Y, T, Z, X, and Q are as defined.

[0404] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where W is a N, and where R1- R9, Y, T, Z, X, and Q are as defined.

[0405] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where W is a O, and where R1- R9, Y, T, Z, X, and Q are as defined.

[0406] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where W is a an alkyl having 1 to 4 carbon atoms, and where R1- R9, Y, T, Z, X, and Q are as defined.

[0407] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where W is a an alkenyl having 1 to 4 carbon atoms, and where R1- R9, Y, T, Z, X, and Q are as defined.

[0408] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Z is a bond, and where R1- R9, W, T, Y, X, and Q are as defined.

[0409] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Z is a C, and where R1- R9, W, T, Y, X, and Q are as defined. An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Z is a N, and where R1- R9, W, T, Y, X, and Q are as defined.

[0410] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Z is a O, and where R1- R9, W, T, Y, X, and Q are as defined.

[0411] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Z is a an alkyl having 1 to 4 carbon atoms, and where R1- R9, W, T, Y, X, and Q are as defined.

[0412] An embodiment of the invention includes a compound of Formula (I), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Z is a an alkenyl having 1 to 4 carbon atoms, and where R1- R9, W, T, Y, X, and Q are as defined.

[0413] Formula II

[0414] In a further embodiment, the invention may be a compound of Formula II or pharmaceutically acceptable salts or esters thereof: wherein R1and R6-R9is independently -H, -CN, -COOH, -CONH2, B(ORa)2, an acid isostere, a halo, Cnalkyl, Cnalkenyl, Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein the halo is selected from the group consisting of -F, -Cl, -Br, -I, -At, and -Ts, wherein the Rais H or an alkyl, wherein the B is boron, wherein n is 1 - 10, wherein each of R2- R5are independently -H, -CN, -COOH, -COOMe, -COMB, B(ORa)2, the acid isostere, the halo, -CONHOH, -NH-SCh-Ci-Cr.-alkyl, -NHSO2Ar, the Cnalkyl, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein the Ar of -MISCkAr is selected from phenyl, naphthyl, pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothi azole, 2,1,3-benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4-tetrahydroquinoline, 3,4-dihydro-2H-1,4-benzoxazine, 1,5- naphthyridine, 1,8-naphthyridine, acridine, phenazine, and xanthene, wherein each of the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl is unsubstituted or substituted with a quantity of substituents being between 1-5, wherein each of the substituents is the same or different, wherein each of the substituents is selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, and -Cq-U- Cq, wherein each q of -Cq-U-Cqis independently 0 to 10, wherein the U of -Cq-U-Cqis any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, S02, or N(R1)(R1), wherein each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein each R1of N(R1)(R1) is unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, wherein Q is a bond or O, wherein X is C, N, O, or S such that R6is not present if X is O or S, wherein X is C, N, O, or S, and wherein n is 0, 1, 2, or 3.

[0415] In some embodiments, the invention includes compounds of Formula II, wherein a heterocycloalkyl group is formed by bonding two of R7, R8, or R9to form:

[0416] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is -CN, and where R2- R5, Q and X are as defined.

[0417] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is -COOH, and where R2- R5, Q and X are as defined.

[0418] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is -CONH2, and where R2- R5, Q and X are as defined.

[0419] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is B(ORa)2, where B of B(ORa)2 is boron, where Raof B(ORa)2is H, and where R2- R5, Q and X are as defined.

[0420] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is B(ORa)2, where B of B(ORa)2is boron, where Raof B(ORa)2is an alkyl, and where R2- R5, Q and X are as defined.

[0421] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is an acid isostere as disclosed herein, and where R2- R5, Q and X are as defined.

[0422] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a halo, and where R2- R5, Q and X are as defined.

[0423] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl, where n of the Cnalkyl is 1 - 10, and where R2- R5, Q and X are as defined.

[0424] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is unsubstituted, where n of the Cnalkyl is 1 - 10, and where R2- R5, Q and X are as defined.

[0425] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted with 1-5 substituents, where n of Cnalkyl is 1 - 10, where each substituent is the same or different, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, - C(O)alkyl, or -Cq-U-Cq, and where R2- R5, Q and X are as defined.

[0426] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted with 1-5 substituents, where n of Cnalkyl is 1 - 10, where at least one substituent is -Cq-U-Cq, where each q of -Cq-U- Cqis independently 0 to 10, where the U of -Cq-U-Cqis any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and where R2- R5, Q and X are as defined.

[0427] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted with 1-5 substituents, where n of Cnalkyl is 1 - 10, where at least one substituent is -Cq-U-Cq, where each q of -Cq-U- Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and where R2- R5, Q and X are as defined.

[0428] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is H, and where R2- R5, Q and X are as defined.

[0429] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is2H, and where R2- R5, Q and X are as defined.

[0430] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where the substituent is a halo, and where R2- R5, Q and X are as defined.

[0431] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an amino group, and where R2- R5, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an alkoxy group, and where R2- R5, Q and X are as defined.

[0432] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is a cyano group, and where R2- R5, Q and X are as defined.

[0433] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an aminoalkyl-, and where R2- R5, Q and X are as defined.

[0434] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an (amino)alkoxy-, and where R2- R5, Q and X are as defined.

[0435] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an -alkyl group, and where R2- R5, Q and X are as defined.

[0436] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an -alkenyl group, and where R2- R5, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an -alkynyl group, and where R2- R5, Q and X are as defined.

[0437] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an alkoxy- group, and where R2- R5, Q and X are as defined.

[0438] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is a hydroxy group, and where R2- R5, Q and X are as defined.

[0439] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an - alkylhydroxy group, and where R2- R5, Q and X are as defined.

[0440] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an aryloxy- group, and where R2- R5, Q and X are as defined.

[0441] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an - alkyl(aryl) group, and where R2- R5, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is an (alkoxyalkyl)amino- group, and where R2- R5, Q and X are as defined.

[0442] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is an aryl group, and where R2- R5, Q and X are as defined.

[0443] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is an - aryl(halo) group, and where R2- R5, Q and X are as defined.

[0444] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is a - heteroaryl group, and where R2- R5, Q and X are as defined.

[0445] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is a hydroxyl-alkyl- group, and where R2- R5, Q and X are as defined.

[0446] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is a hydroxyl-aryl- group, and where R2- R5, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is an (aryl)alkyl- group, and where R2- R5, Q and X are as defined.

[0447] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is a - S(O)2-alkyl group, and where R2- R5, Q and X are as defined.

[0448] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is a - S(O)2-aryl group, and where R2- R5, Q and X are as defined.

[0449] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one the substituent is a - C(O)alkyl group, and where R2- R5, Q and X are as defined.

[0450] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -Cq-U-Cq, and where R2- R5, Q and X are as defined.

[0451] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U is heteroaryl, and where R2- R5, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U is cycloalkyl, and where R2- R5, Q and X are as defined.

[0452] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U is heterocycloalkyl, and where R2- R5, Q and X are as defined.

[0453] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U is O, and where R2- R5, Q and X are as defined.

[0454] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U is S, and where R2- R5, Q and X are as defined.

[0455] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U is SO2, and where R2- R5, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, and where R2- R5, Q and X are as defined.

[0456] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R2- R5, Q and X are as defined.

[0457] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted, where n of Cnalkyl is 1 - 10, where a quantity of the substituents is 1-5, where at least one substituent is -Cq-U-Cq, where each q of -Cq-U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where each substituent is the same or is different, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R2- R5, Q and X are as defined.

[0458] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkyl that is substituted with 1-5 substituents that are the same or are different, where n of Cnalkyl is 1 - 10, and where R2- R5, Q and X are as defined.

[0459] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnalkenyl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of Cnalkenyl is 1 - 10, and where R2- R5, Q and X are as defined.

[0460] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaryl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of Cnaryl is 1 - 10, and where R2- R5, Q and X are as defined.

[0461] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnaminoalkyl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of Cnaminoalkyl is 1 - 10, and where R2- R5, Q and X are as defined.

[0462] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnhaloalkyl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of Cnhaloalkyl is 1 — 10, and where R2- R5, Q and X are as defined.

[0463] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheteroaryl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of Cnheteroaryl is 1 — 10, and where R2- R5, Q and X are as defined.

[0464] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cncycloalkyl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of Cncycloalkyl is 1 - 10, and where R2- R5, Q and X are as defined.

[0465] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R1and R6-R9is a Cnheterocycloalkyl that is unsubstituted or is substituted with 1-5 substituents that are the same or are different, where n of Cnheterocycloalkyl is 1 - 10, and where R2- R5, Q and X are as defined.

[0466] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -H, and where R1, R6-R9, Q and X are as defined.

[0467] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -CN, and where R1, R6-R9, Q and X are as defined.

[0468] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -COOH, and where R1, R6-R9, Q and X are as defined.

[0469] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -COOMe, and where R1, R6-R9, Q and X are as defined.

[0470] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -CONH2, and where R1, R6-R9, Q and X are as defined.

[0471] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is B(ORa)2, where B is boron, where Rais H, and where R1, R6-R9, Q and X are as defined.

[0472] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is B(ORa)2, where B is boron, where Rais an alkyl, and where R1, R6-R9, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the acid isostere, and where R1, R6-R9, Q and X are as defined.

[0473] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the halo, and where R1, R6-R9, Q and X are as defined.

[0474] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -CONHOH, and where R1, R6-R9, Q and X are as defined.

[0475] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NH- SO2-C1-C6-alkyl, and where R1, R6-R9, Q and X are as defined.

[0476] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is phenyl, and where R1, R6-R9, Q and X are as defined.

[0477] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is naphthyl, and where R1, R6-R9, Q and X are as defined.

[0478] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is pyrrole, and where R1, R6-R9, Q and X are as defined.

[0479] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is imidazole, and where R1, R6- R9, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is thiophene, and where R1, R6- R9, Q and X are as defined.

[0480] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isothiazole, and where R1, R6- R9, Q and X are as defined.

[0481] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is thiadiazole, and where R1, R6- R9, Q and X are as defined.

[0482] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is oxazole, and where R1, R6-R9,

[0483] Q and X are as defined.

[0484] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isoxazole, and where R1, R6-R9, Q and X are as defined.

[0485] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is oxadiazole, and where R1, R6- R9, Q and X are as defined.

[0486] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is pyridine, and where R1, R6-R9, Q and X are as defined.

[0487] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is pyrazine, and where R1, R6-R9, Q and X are as defined.

[0488] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is pyrimidine, and where R1, R6- R9, Q and X are as defined.

[0489] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is pyridazine, and where R1, R6- R9, Q and X are as defined.

[0490] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is pyrazole, and where R1, R6-R9, Q and X are as defined.

[0491] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is triazole, and where R1, R6-R9,

[0492] Q and X are as defined.

[0493] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is tetrazole, and where R1, R6-R9, Q and X are as defined.

[0494] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is chroman, and where R1, R6-R9, Q and X are as defined.

[0495] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isochroman, and where R1, R6- R9, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is quinoline, and where R1, R6-R9, Q and X are as defined.

[0496] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is quinoxaline, and where R1, R6- R9, Q and X are as defined.

[0497] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isoquinoline, and where R1, R6- R9, Q and X are as defined.

[0498] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is phthalazine, and where R1, R6- R9, Q and X are as defined.

[0499] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is cinnoline, and where R1, R6-R9, Q and X are as defined.

[0500] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is quinazoline, and where R1, R6- R9, Q and X are as defined.

[0501] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is indole, and where R1, R6-R9, Q and X are as defined.

[0502] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isoindole, and where R1, R6-R9, Q and X are as defined.

[0503] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is indoline, and where R1, R6-R9, Q and X are as defined.

[0504] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isoindoline, and where R1, R6- R9, Q and X are as defined.

[0505] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is benzothiophene, and where R1, R6-R9, Q and X are as defined.

[0506] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is benzofuran, and where R1, R6- R9, Q and X are as defined.

[0507] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is isobenzofuran, and where R1, R6-R9, Q and X are as defined.

[0508] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is benzoxazole, and where R1, R6- R9, Q and X are as defined.

[0509] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 2,1,3-benzoxadiazole, and where R1, R6-R9, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is benzothi azole, and where R1, R6-R9, Q and X are as defined.

[0510] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 2,1,3-benzothiazole, and where R1, R6-R9, Q and X are as defined.

[0511] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 2,1,3-benzoselenadiazole, and where R1, R6-R9, Q and X are as defined.

[0512] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is benzimidazole, and where R1, R6-R9, Q and X are as defined.

[0513] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is indazole, and where R1, R6-R9, Q and X are as defined.

[0514] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is benzodioxane, and where R1, R6-R9, Q and X are as defined.

[0515] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is indane, and where R1, R6-R9, Q and X are as defined.

[0516] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 1,2,3,4-tetrahydroquinoline, and where R1, R6-R9, Q and X are as defined.

[0517] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 3,4-dihydro-2H-l,4- benzoxazine, and where R1, R6-R9, Q and X are as defined.

[0518] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 1,5- naphthyridine, and where R1, R6-R9, Q and X are as defined.

[0519] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is 1,8-naphthyridine, and where R1, R6-R9, Q and X are as defined.

[0520] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is acridine, and where R1, R6-R9, Q and X are as defined.

[0521] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is phenazine, and where R1, R6- R9, Q and X are as defined.

[0522] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is -NHSO2Ar, where Ar is xanthene, and where R1, R6-R9, Q and X are as defined.

[0523] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is unsubstituted, where n is 1 - 10, and where R1, R6-R9, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is substituted with 1-5 substituents that are the same or are different, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, where n of Cnalkyl is 1 — 10, and where R1, R6-R9, Q and X are as defined.

[0524] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is substituted, where the quantity of substituents is 1-5, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U is aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), where n of Cnalkyl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0525] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is substituted with 1-5 substituents that are the same or are different, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U- Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where n of Cnalkyl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0526] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is substituted, where n of Cnalkyl is 1 — 10, where the quantity of substituents is 1-5, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is unsubstituted, and where R1, R6-R9, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkyl that is substituted, where n of Cnalkyl is 1 — 10, where the quantity of substituents is 1-5, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U is N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents that are the same or are different, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0527] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkenyl that is unsubstituted, where n of Cnalkenyl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0528] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkenyl that is substituted, where n of Cnalkenyl is 1 - 10, where the quantity of substituents is 1-5 that are the same or are different, where each substituted is: H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0529] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkenyl that is substituted with 1-5 substituents, where n of Cnalkenyl is 1 - 10, where at least one substituent is -Cq-U-Cq,, where each q of -Cq- U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and where R1, R6-R9, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkenyl that is substituted with 1-5 substituents, where n of Cnalkenyl is 1 - 10, where at least one substituent is -Cq-U-Cq., where each q of -Cq- U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0530] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkynyl, where n of Cnalkynyl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0531] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkynyl that is unsubstituted, where n of Cnalkynyl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0532] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkynyl that is substituted with 1-5 substituents that are the same or are different, where n of Cnalkynyl is 1 - 10, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0533] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkynyl that is substituted, where n of the Cnalkynyl is 1 - 10, where the quantity of substituents is 1-5, where each substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and where R1, R6-R9, Q and X are as defined.

[0534] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnalkynyl that is substituted, where n of the Cnalkynyl is 1 - 10, where the quantity of substituents is 1-5, where each substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0535] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaryl, where n of Cnaryl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0536] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaryl that is unsubstituted, where n of Cnaryl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0537] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaryl that is substituted with 1-5 substituents that are the same or are different, where n of Cnaryl is 1 - 10, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0538] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaryl that is substituted with 1-5 substituents that are the same or are different, where n of Cnaryl is 1 - 10, where at least one substituent is -Cq- U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and where R1, R6-R9, Q and X are as defined.

[0539] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaryl that is substituted with 1-5 substituents that are the same or are different, where n of Cnaryl is 1 - 10, where at least one substituent is -Cq- U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and - C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0540] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaminoalkyl, where n of Cnaminoalkyl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0541] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaminoalkyl that is unsubstituted, where n of Cnaminoalkyl is 1 - 10, and where R1, R6-R9, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaminoalkyl that is substituted with 1-5 substituents that are the same or are different, where n of Cnaminoalkyl is 1 - 10, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0542] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaminoalkyl that is substituted with 1-5 substituents that are the same or are different, where n of Cnaminoalkyl is 1 - 10, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, orN(R1)(R1), and where R1, R6-R9, Q and X are as defined.

[0543] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnaminoalkyl that is substituted with 1-5 substituents that are the same or are different, where n of Cnaminoalkyl is 1 - 10, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, - alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, - aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2- aryl, and -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0544] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnhaloalkyl, where n of Cnhaloalkyl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0545] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnhaloalkyl that is unsubstituted, where n of Cnhaloalkyl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0546] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnhaloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of Cnhaloalkyl is 1 - 10, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0547] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnhaloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of Cnhaloalkyl is 1 - 10, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and where R1, R6-R9, Q and X are as defined.

[0548] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnhaloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of Cnhaloalkyl is 1 - 10, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and - C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0549] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheteroaryl, where n of the Cnheteroaryl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0550] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheteroaryl that is unsubstituted, where n of the Cnheteroaryl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0551] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheteroaryl that is substituted with 1-5 substituents that are the same or are different, where n of Cnheteroaryl is 1 - 10, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0552] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheteroaryl that is substituted with 1-5 substituents that are the same or are different, where n of Cnheteroaryl is 1 - 10, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq- U-Cqis any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and where R1, R6-R9, Q and X are as defined.

[0553] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheteroaryl that is substituted with 1-5 substituents that are the same or are different, where n of Cnheteroaryl is 1 - 10, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq- U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and - C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0554] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cncycloalkyl, where n of Cncycloalkyl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0555] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cncycloalkyl that is unsubstituted, where n of Cncycloalkyl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0556] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cncycloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of Cncycloalkyl is 1 - 10, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, or -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0557] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cncycloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of Cncycloalkyl is 1 - 10, where at least one substituent is -Cq-U-Cq., where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq- U-Cqis any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and where R1, R6-R9, Q and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cncycloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of Cncycloalkyl is 1 - 10, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq- U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and - C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0558] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheterocycloalkyl, where n of the Cnheterocycloalkyl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0559] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheterocycloalkyl that is unsubstituted, where n of the Cnheterocycloalkyl is 1 - 10, and where R1, R6-R9, Q and X are as defined.

[0560] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheterocycloalkyl that is substituted with 1-5 substituents that are the same or are different, where n of Cnheterocycloalkyl is 1 - 10, where each substituent is H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, - alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, - aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2- aryl, or -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0561] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheterocycloalkyl that is substituted with 1-5 subsistent that are the same or are different, where n of Cnheterocycloalkyl is 1 - 10, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), and where R1, R6-R9, Q and X are as defined.

[0562] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where at least one of R2- R5is the Cnheterocycloalkyl that is substituted with 1-5 subsistent that are the same or are different, where n of Cnheterocycloalkyl is 1 - 10, where at least one substituent is -Cq-U-Cq,, where each q of -Cq-U-Cqis independently 0 to 10, where the U of -Cq-U-Cqis N(R1)(R1), where each R1of N(R1)(R1) is independently hydrogen, the Cnalkyl, the Cnalkenyl, the Cnalkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, where each R1of N(R1)(R1) is substituted with 1-5 substituents, where the substituent of each R1of N(R1)(R1) is the same or different and are independently selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, - alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, - aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2- aryl, and -C(O)alkyl, and where R1, R6-R9, Q and X are as defined.

[0563] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Q is a bond, and where R1- R9and X are as defined.

[0564] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where Q is O, and where R1- R9and X are as defined.

[0565] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is C, and where R1- R9and X are as defined.

[0566] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is N, and where R1- R9, R1- R9and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is O, R6is not present, and where R1- R5, R7- R9, R1- R9and X are as defined. An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where X is S, R6is not present, and where R1- R5, R7- R9, R1- R9and X are as defined.

[0567] An embodiment of the invention includes a compound of Formula (II), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 - 3, and where R1- R9, Q and X are as defined.

[0568] Formula III

[0569] Additional embodiments of the invention include compounds of Formula III or pharmaceutically acceptable salts or esters thereof: wherein R1is selected from the group consisting of: -CN, alkyl, -H, halo,2H, amino, alkoxy, aminoalkyl, (amino)alkoxy, alkenyl, alkynyl, alkoxy, hydroxy, alkylhydroxy, aryloxy, alkyl(aryl), (alkoxyalkyl)amino, aryl, aryl(halo), heteroaryl, hydroxyl-alkyl, hydroxyl-aryl, (aryl)alkyl, C(O)OH, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, and C(O)NH2, wherein each of R3and R4are independently -H, the halo, Cnalkyl, Cnalkyl, the Cnalkenyl, the Cnalkynyl, the Cnaryl, the Cnaminoalkyl, the Cnhaloalkyl, the Cnheteroaryl, the Cncycloalkyl, the Cnheterocycloalkyl, and -Cq-U-Cq, wherein n is 1 - 10, wherein each q of -Cq-U-Cqis independently 0 to 10, wherein the U of -Cq-U-Cqis any one of O, S, SO2, or N(R1)(R1), wherein each R1of N(R1)(R1) independently hydrogen, wherein each of the Cnalkyl, the Cnalkenyl, the Cnalkynyl, the Cnaryl, the Cnaminoalkyl, the Cnhaloalkyl, the Cnheteroaryl, the Cncycloalkyl, or the Cnheterocycloalkyl is unsubstituted or substituted with a quantity of substituents being between 1-5, wherein each of the substituents is the same or different, wherein each of the substituents is selected from the group consisting of H,2H, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, and -C(O)alkyl, wherein R6is independently H or alkyl, wherein each of R7and R8are independently hydrogen,2H, fluoro or alkyl, wherein R6and R7are bonded with an adjoining R group to form a fused group, wherein the fused group is selected from the group consisting of: a fused cycloalkyl, a fused heterocycloalkyl, a fused aryl, and a fused heteroaryl ring, wherein the fused group comprises between 4 to 10 carbon atoms, wherein n of Formula III is 0 or 1, wherein Q is a bond or O, wherein X is C, N, O, or S such that R6is not present if X is O or S, and wherein Z1or W1are independently C, N, O, or S.

[0570] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0, and where R1, R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0571] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 1, and where R1, R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0572] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where Q is a bond, and where R1, R3-R4, R6-R8, X, Z1, and W1are as defined.

[0573] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where Q is O, and where R1, R3-R4, R6-R8, X, Z1, and W1are as defined.

[0574] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where X is C, and where R1, R3-R4, R6-R8, Q, Z1, and W1are as defined.

[0575] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where X is N, and where R1, R3-R4, R6-R8, Q, Z1, and W1are as defined.

[0576] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where X is O, where R6is not present, and where R1, R3-R4, R7-R8,

[0577] Q, Z1, and W1are as defined.

[0578] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where X is S, where R6is not present, and where R1, R3-R4, R7-R8, Q, Z1, and W1are as defined.

[0579] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where Z1is C, and where R1, R3-R4, R7-R8, Q, X, and W1are as defined.

[0580] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where Z1is N, and where R1, R3-R4, R7-R8, Q, X, and W1are as defined. An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where Z1is O, and where R1, R’-R4, R7-R8, Q, X, and W1are as defined.

[0581] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where Z1is S, and where R1, R3-R4, R7-R8, Q, X, and W1are as defined.

[0582] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where W1is C, and where R1, R3-R4, R7-R8, Q, X, and Z1are as defined.

[0583] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where W1is N, and where R1, R3-R4, R7-R8, Q, X, and Z1are as defined.

[0584] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where W1is O, and where R1, R3-R4, R7-R8, Q, X, and Z1are as defined.

[0585] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where W1is S, and R1, R3-R4, R7-R8, Q, X, and Z1are as defined.

[0586] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is -CN, and where R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0587] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is alkyl, and where R3-R4, R6-R8, Q, X, Z1, and W1are as defined. An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is -H, and where R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0588] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is a halo, and where R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0589] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is2H, and where R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0590] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is an amino group, and where R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0591] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is an alkoxy group, and where R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0592] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is an aminoalkyl group, and where R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0593] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is an (amino)alkoxy group, and where R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0594] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is an alkenyl group, and where R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0595] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is an alkynyl group, and where R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0596] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is an alkoxy group, and where R3-R4, R6-R8, Q, X, Z1, and W1are as defined.

[0597] An embodiment of the invention includes a compound of Formula (III), or pharmaceutically acceptable salts or esters thereof, where the various moieties are independently selected, where n is 0 or 1, where R1is a hydroxy grou...

Claims

CLAIMSWhat is claimed is:

1. A compound of Formula I comprising:Formula I or pharmaceutically acceptable salts or esters thereof, wherein:R1- R9are independently hydrogen, CN, COOH, CONH2, B(ORa)2(where Rais H or alkyl), an acid isostere, halo, C1-C10alkyl, C1-C10alkenyl, C1-C10alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein any of R2- R9may be bonded with an adjoining R group thereby forming a fused cycloalkyl, fused heterocycloalkyl, fused aryl, or fused heteroaryl ring having from 4 to 10 carbon atoms; wherein each of said C1-C10alkyl, C1-C10alkenyl, C1-C10alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is either unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of hydrogen, deuterium, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl,-C(O)alkyl; -Cq-U-Cq,where each q is independently 0 to 10 and U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl ,0, S, SO2, orN(R1) (R1), wherein each R1is independently hydrogen, C1-C10 alkyl, C1-C10 alkenyl, C1-C10 alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is either unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of hydrogen, deuterium, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, - alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl- aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl;Q is a bond or O;X is C, N, O, or S, with the proviso that R6is not present if X is O or S;wherein “A” is a saturated or unsaturated ring depicted by and Y, T, W, and Z are independently a bond, C, N, O, or alkyl or alkenyl having 1 to 4 carbon atoms; and n is 0, 1, 2, or 3.

2. The compound of claim 1 wherein at least one of: R1and R2, R2and R3, R3and R4, R4and R5, R5and R6, R7and R8,or R8and R9are bonded forming a fused heteroaryl or fused heterocycloalkyl.

3. The compound of claim 1 wherein R3is a Cnalkyl, and wherein the n is between 3-8.

4. The compound of claim 1 wherein R1is the halo.

5. The compound of claim 1 wherein Q comprises the bond.

6. A compound of Formula II comprising:Formula II or pharmaceutically acceptable salts or esters thereof wherein:R1- R9are independently hydrogen, CN, COOH, CONH2, B(ORa)2(where Rais H or alkyl), an acid isostere, halo, C1-C10alkyl, C1-C10alkenyl, C1-C10alkynyl, aryl, aminoalkyl, haloalkyl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein any of R2- R9may be bonded with an adjoining R group thereby forming a fused cycloalkyl, fused heterocycloalkyl, fused aryl, or fused heteroaryl ring having from 4 to 10 carbon atoms and wherein each of said C1-C10alkyl, Ci- C10alkenyl, Ci-C10alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is either unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of hydrogen, deuterium, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, - alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl- aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl; -Cq-U-Cq,where each q is independently 0 to 10 and U is any one of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, O, S, SO2, or N(R1)(R1), wherein each R1is independently hydrogen, C1-C10alkyl, C1-C10alkenyl, C1-C10alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is either unsubstituted or substituted with 1, 2, 3, 4or 5 substituents which can be the same or different and are independently selected from the group consisting of hydrogen, deuterium, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl(halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl,-C(O)alkyl;Q is a bond or O;X is C, N, O, or S, with the proviso that R6is not present if X is O or S;X is C, N, O, or S; and n is 0, 1, 2, or 3.

7. The compound of claim 6 wherein said heterocycloalkyl formed by bonding two of R7, R8or R9is, or8. A compound of Formula III comprising:Formula III or pharmaceutically acceptable salts or esters thereof, wherein:R1is cyano, alkyl, hydrogen, halo, deuterium, amino, alkoxy, aminoalkyl, (amino)alkoxy, alkenyl, alkynyl, alkoxy, hydroxy, alkylhydroxy, aryloxy, alkyl(aryl), (alkoxyalkyl)amino, aryl, aryl(halo), heteroaryl, hydroxyl-alkyl, hydroxyl-aryl, (aryl)alkyl, C(O)OH, -S(O)2-alkyl, -S(O)2-aryl, -C(O)alkyl, or C(O)NH2;R3and R4are independently halo or Ci-Cio alkyl, -Cq-U-Cq.where each q is independently 0 to 10 and U is any one of O, S, SO2, or N(R1)(R1), wherein each R1is independently hydrogen, C1-C10 alkyl, C1-C10 alkenyl, C1-C10 alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is either unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of hydrogen, deuterium, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, - alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, -aryl (halo), - heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, -S(O)2-aryl, - C(O)alkyl;R6is independently H or alkyl;R7and R8are independently hydrogen, deuterium, fluoro or alkyl; wherein R6- R7may be bonded with an adjoining R group thereby forming a fused cycloalkyl, fused heterocycloalkyl, fused aryl, or fused heteroaryl ring having from 4 to 10 carbon atoms and wherein each of said C1-C10 alkyl, C1-C10 alkenyl, C1-C10 alkynyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is either unsubstituted or substituted with 1, 2, 3, 4 or 5 substituents which can be the same or different and are independently selected from the group consisting of hydrogen, deuterium, halo, amino, alkoxy, cyano, aminoalkyl-, (amino)alkoxy-, -alkyl, -alkenyl, -alkynyl, alkoxy-, hydroxy, -alkylhydroxy, aryloxy-, -alkyl(aryl), (alkoxyalkyl)amino-, -aryl, - aryl(halo), -heteroaryl, hydroxyl-alkyl-, hydroxyl-aryl-, (aryl)alkyl-, -S(O)2-alkyl, - S(O)2-aryl, -C(O)alkyl n is 0 or 1;Q is a bond or O;X is C, N, O, or S, with the proviso that R6is not present if X is O or S; andZ1or W1are independently C, N, O, or S.

9. The compound of claim 8 wherein X is N.

10. The compound of claim 8 wherein R6is hydrogen and X is N.

11. The compound of claim 8 wherein R3is alkyl and R1is cyano.

12. The compound of claim 8 wherein X is N, and n=0.

13. The compound of claim 8 wherein X is N, and n=l.

14. The compounds of claim 8 wherein X is N, and Z1and W1are C.

15. A compound selected from the group consisting of: 3-{[6-butyl-4-(4- fluorophenyl)quinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 3-{[4-(4- fluorophenyl)-6-hexylquinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-{ [4-(4- fluorophenyl)-6-pentylquinolin-2-yl](methyl)amino}acetic acid, 2-{ [4-(4-fluorophenyl)- 6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-3-methyl-4-(morpholin-4- yl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexyl-3- methylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4,6-bis(4-fluorophenyl)quinolin-2- yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl](2- methylpropyl)amino}acetic acid, 2-{ [4-(4-fluorophenyl)-6-hexylquinolin-2- yl](propyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-hexylquinolin-2-yl]amino}acetic acid, 2-{ethyl[4-(4-fluorophenyl)-6-hexylquinolin-2-yl]amino}acetic acid, 2-{[6-hexyl-4- (pyridin-3-yloxy)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-4-(pyridin-4- yloxy)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-fluorophenoxy)-6- hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{ [4-(4-fluorophenoxy)-6-hexylquinolin- 2-yl](methyl)amino}acetic acid, 2-{[4-(4-fluorophenyl)-6-octylquinolin-2-yl](2- methylpropyl)amino}acetic acid, 2-{ [4-(4-fluorophenyl)-6-octylquinolin-2- yl](propyl)amino}acetic acid, 2-{ethyl[4-(4-fluorophenyl)-6-octylquinolin-2-yl]amino}acetic acid, 2-{methyl[6-octyl-4-(pyridin-3-yloxy)quinolin-2-yl]amino}acetic acid, 2-{methyl[6-octyl-4-(pyridin-4-yloxy)quinolin-2-yl]amino}acetic acid, 2-{[4-(3- fluorophenoxy)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-{ [4-(4- fluorophenoxy)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-decyl-4-(4- fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{ [4-(4-fluorophenyl)-6- heptylquinolin-2-yl](methyl)amino}acetic acid, 2-{ [4-(4-fluorophenyl)-6-octylquinolin- 2-yl](methyl)amino}acetic acid, 2-[(6-hexylquinolin-2-yl)(methyl)amino]acetic acid, 2- {2-[(carboxymethyl)(methyl)amino]-6-hexylquinolin-4-yl}benzoic acid, 2-{[4-(4,4- difluoropiperidin-l-yl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3,3- difluoropyrrolidin-l-yl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-4- (morpholin-4-yl)quinolin-2-yl](methyl)amino}acetic acid, 2-{ [6-butyl-4-(2-methyl- pyridin-4-yl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3,5-dimethyl-l,2-oxazol-4- yl)-6-hexylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3-cyanophenyl)-6- hexylquinolin-2-yl](methyl)amino}acetic acid, 3-{[4-(3-cyanophenyl)-6-hexylquinolin-2- yl](methyl)amino}butanoic acid, 3-[(6-hexyl-4-phenylquinolin-2-yl)(methyl)amino]-2- methylpropanoic acid, 2-[methyl(6-pentanamido-4-phenylquinolin-2-yl)amino]acetic acid, 2-{methyl[6-(pentyloxy)-4-phenylquinolin-2-yl]amino}acetic acid, 2-[(7-bromo-4- phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-[(7-hexyl-4-phenylquinolin-2- yl)(methyl)amino]acetic acid, 2-[methyl(6-octyl-4-phenylquinolin-2-yl)amino]acetic acid, 3-{[6-hexyl-4-(pyridin-3-yl)quinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-{[6-hexyl-4-(pyridin-3-yl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3- cyanophenyl)-6-hexylquinolin-2-yl]oxy} acetic acid, 3-{[4-(3-cyanophenyl)-6- hexylquinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-{[4-(3-cyanophenyl)-6- hexylquinolin-2-yl](methyl)amino}acetic acid, 1 -[6-hexyl-4-(pyri din-3 -yl)quinolin-2- yl]piperidine-3 -carboxylic acid, l-(6-hexyl-4-phenylquinolin-2-yl)piperidine-3- carboxylic acid, 2-{ [6-butyl-4-(4-hydroxyphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-hydroxyphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{ [6- butyl-4-(2-hydroxyphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{ [6-butyl-4-(4- fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3- fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{ [6-butyl-4-(2- fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{ [6-butyl-4-(4-methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3- methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{ [6-butyl-4-(2- methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{ [6-butyl-4-(4- cyanophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{ [6-butyl-4-(4- carbamoylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{ [6-butyl-4-(pyridin-4- yl)quinolin-2-yl](methyl)amino}acetic acid, 6-butyl-2-(carboxymethoxy)-4- phenylquinoline-3 -carboxylic acid, 2-{[6-butyl-4-(pyridin-3-yl)quinolin-2- yl](methyl)amino}acetic acid, l-[6-butyl-4-(3-cyanophenyl)quinolin-2-yl]piperidine-3- carboxylic acid, 4-(6-butyl-4-phenylquinolin-2-yl)morpholine-2-carboxylic acid, l-(6- butyl-4-phenylquinolin-2-yl)piperidine-3 -carboxylic acid, 3-{[6-butyl-4-(3- cyanophenyl)quinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 3-{ [6-butyl-4- (pyridin-3-yl)quinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 3-[(6-butyl-4- phenylquinolin-2-yl)(methyl)amino]-2-methylpropanoic acid, 3-[(6-butyl-4- phenylquinolin-2-yl)(methyl)amino]butanoic acid, 3-[(6-butyl-4-phenylquinolin-2- yl)(methyl)amino]propanoic acid, N-(6-butyl-4-(3-cyanophenyl)quinolin-2-yl)-N- methylvaline, 2-{[4-(3-cyanophenyl)-6-pentylquinolin-2-yl]oxy}acetic acid, 2-{[4-(3- carbamoylphenyl)-6-pentylquinolin-2-yl]oxy}acetic acid, 2-{[4-(3-cyanophenyl)-6- propylquinolin-2-yl]oxy} acetic acid, 2-{[4-(3-carbamoylphenyl)-6-propylquinolin-2- yl]oxy}acetic acid, 2-{[4-(3-carbamoylphenyl)-6-ethylquinolin-2-yl]oxy}acetic acid, 2- {[6-bromo-4-(3-cyanophenyl)quinolin-2-yl]oxy}acetic acid, 2-{[6-bromo-4-(3- carbamoylphenyl)quinolin-2-yl]oxy }acetic acid, 2-{ [6-butyl-4-(3-cyanophenyl)quinolin- 2-yl]oxy}acetic acid, 2-{[6-butyl-4-(3-carbamoylphenyl)quinolin-2-yl]oxy}acetic acid, 2- {[4-(3-cyanophenyl)-6-pentylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3- carbamoylphenyl)-6-pentylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3- cyanophenyl)-6-propylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3- carbamoylphenyl)-6-propylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3- cyanophenyl)-6-ethylquinolin-2-yl](methyl)amino}acetic acid, 2-{[4-(3- carbamoylphenyl)-6-ethylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-bromo-4-(3- cyanophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-bromo-4-(3- carbamoylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3- cyanophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-carbamoylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{2-[(6-chloro-4- phenylquinolin-2-yl)(methyl)amino]acetamido}acetic acid, 2-[methyl(6-pentyl-4- phenylquinolin-2-yl)amino]acetic acid, 2-[methyl(4-phenyl-6-propylquinolin-2- yl)amino]acetic acid, 2-[(6-ethyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, l-(6- hexyl-4-phenylquinolin-2-yl)pyrrolidine-2-carboxylic acid, 6-hexyl-4-phenyl-2- (piperidin-l-yl)quinoline, 2-[(6-hexyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid,1 -(6-butyl-4-phenylquinolin-2-yl)pyrrolidine-2-carboxylic acid, 6-butyl-4-phenyl-2- (piperidin-l-yl)quinoline, 2-[(6-bromo-4-phenylquinolin-2-yl)oxy]acetic acid, 2-[(6- bromo-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-[(6-pentyl-4-phenylquinolin- 2-yl)oxy]acetic acid, 2-[(4-phenyl-6-propylquinolin-2-yl)oxy]acetic acid, 2-[(6-ethyl-4- phenylquinolin-2-yl)oxy]acetic acid, 2-[(6-chloro-4-phenylquinolin-2-yl)oxy]acetic acid, 2-[(6-butyl-4-phenylquinolin-2-yl)oxy]acetic acid, 2-[(6-butyl-4-phenylquinolin-2- yl)(methyl)amino]acetic acid, l-(6-chloro-4-phenylquinolin-2-yl)pyrrolidine-2- carboxylic acid, 2-[(6-chloro-4-phenylquinolin-2-yl)(methyl)amino]propanoic acid, 2- [(6-chloro-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 6-chloro-4-phenyl-2- (piperidin-l-yl)quinoline, 3-{[6-butyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}- 2-methylpropanoic acid, 2-[methyl(6-octyl-4-phenylquinolin-2-yl)amino]acetic acid, 2- { [6-butyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-{methyl[6-octyl- 4-(pyridin-3-yloxy)quinolin-2-yl]amino}acetic acid, 2-{[6-butyl-4-(3- fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2-[(6-hexyl-4-phenylquinolin-2- yl)(methyl)amino]acetic acid, 2-{ [4-(4-fluorophenoxy)-6-octylquinolin-2- yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-methylphenyl)quinolin-2- yl](methyl)amino}acetic acid, 2-[(6-butyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2-{[6-decyl-4-(4-fluorophenyl)quinolin-2-yl](methyl)amino}acetic acid, 2- [methyl(4-phenyl-6-propylquinolin-2-yl)amino]acetic acid, 2-{ [6-butyl-4-(4- methylphenyl)quinolin-2-yl](methyl)amino}acetic acid, 3-[(6-butyl-4-phenylquinolin-2- yl)(methyl)amino]-2-methylpropanoic acid, 2-{ [4-(4-fluorophenyl)-6-pentylquinolin-2- yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(3-cyanophenyl)quinolin-2- yl](methyl)amino}acetic acid, 2-{[6-butyl-4-(2-fluorophenyl)quinolin-2- yl](methyl)amino}acetic acid, 2-{[6-hexyl-4-(pyridin-3-yloxy)quinolin-2- yl](methyl)amino}acetic acid, 2-{[4-(3-fluorophenoxy)-6-octylquinolin-2-yl](methyl)amino}acetic acid, 2-[methyl(6-pentyl-4-phenylquinolin-2-yl)amino]acetic acid, 3-[(6-hexyl-4-phenylquinolin-2-yl)(methyl)amino]-2-methylpropanoic acid, 2- { [4- (3-cyanophenyl)-6-propylquinolin-2-yl](methyl)amino}acetic acid, 2-{[6-hexyl-4- (morpholin-4-yl)quinolin-2-yl](methyl)amino}acetic acid, 3-{[4-(4-fluorophenyl)-6- hexylquinolin-2-yl](methyl)amino}-2-methylpropanoic acid, 2-{ [4-(4-fluorophenyl)-6- hexylquinolin-2-yl](methyl)amino}acetic acid, 3-{[4-(3-cyanophenyl)-6-hexylquinolin-2- yl](methyl)amino}-2-methylpropanoic acid, 2-[methyl({6-[2-(4-methylphenyl)ethyl]-4- phenylquinolin-2-yl})amino]acetic acid, 2-[methyl({6-[2-(3-methylphenyl)ethyl]-4- phenylquinolin-2-yl})amino]acetic acid, 6-hexyl-N-methyl-4-phenyl-N-[(2H-l, 2,3,4- tetrazol-5-yl)methyl]quinolin-2-amine, 2-{methyl[4-phenyl-6-(2-phenylethyl)quinolin-2- yl]amino}acetic acid, 2-({6-[2-(3-chlorophenyl)ethyl]-4-phenylquinolin-2- yl } (methyl)amino)acetic acid, 5 - { [4-phenyl-6-(2-phenylethyl)quinolin-2-yl]methyl } - 1 ,3 - thiazolidine-2,4-dione, 2-({6-[2-(4-chlorophenyl)ethyl]-4-phenylquinolin-2- yl}(methyl)amino)acetic acid, 2-[methyl({4-phenyl-6-[2-(pyridin-3-yl)ethyl]quinolin-2- yl})amino]acetic acid, 2-[methyl({4-phenyl-6-[2-(quinolin-6-yl)ethyl]quinolin-2- yl})amino]acetic acid, 2-[(6-heptyl-4-phenylquinolin-2-yl)(methyl)amino]acetic acid, 2- [methyl({6-[2-(2-methylphenyl)ethyl]-4-phenylquinolin-2-yl})amino]acetic acid, 2- [methyl({4-phenyl-6-[2-(pyridin-2-yl)ethyl]quinolin-2-yl})amino]acetic acid, cis-2-(6- hexyl-4-phenylquinolin-2-yl)cyclopropane-l -carboxylic acid, l-(6-hexyl-4- phenylquinolin-2-yl)-3-methylpyrrolidine-3 -carboxylic acid, 2-[methyl({4-phenyl-6-[2- (pyrimidin-2-yl)ethyl]quinolin-2-yl})amino]acetic acid, 2-[(6-hexyl-4-phenyl-5, 6,7,8- tetrahydroquinolin-2-yl)(methyl)amino]acetic acid, 2-[methyl({4-phenyl-6-[2- (quinoxalin-6-yl)ethyl]quinolin-2-yl})amino]acetic acid, 5-[(6-hexyl-4-phenylquinolin-2- yl)methyl]-l,3-thiazolidine-2,4-dione, 2-({6-[(lE)-hex-l-en-l-yl]-4-phenylquinolin-2- yl } (methyl)amino)acetic acid, 2- {methyl [4-phenyl-6-(3 -phenylpropyl)quinolin-2- yl]amino}acetic acid, 2-[methyl({4-phenyl-6-[2-(l,2,3,4-tetrahydroquinolin-6- yl)ethyl]quinolin-2-yl})amino]acetic acid, 2-({6-[2-(3-methoxyphenyl)ethyl]-4- phenylquinolin-2-yl}(methyl)amino)acetic acid, 2-({6-[2-(l,3-benzothiazol-2-yl)ethyl]-4- phenylquinolin-2-yl}(methyl)amino)acetic acid, 2-{[6-hexyl-4-(pyridin-4-yl)quinolin-2- yl]oxy}propanoic acid, and 3-(6-hexyl-4-phenylquinolin-2-yl)butanoic acid.

16. A method of inhibiting the fatty acid binding protein FABP4 in a mammal, which comprises administering to a mammal an effective amount of a compound of claim 1.

17. A method according to claim 16, wherein the subject is a human.

18. The compound according to claim 1 for use in the prophylaxis or treatment of disorders acting on the fatty acid binding protein FABP4.

19. The compound according to claim 16, wherein the disorders are selected from type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, atherosclerosis, intracranial atherosclerotic disease, non-alcoholic steatohepatitis, asthma, multiple sclerosis, Alzheimer’s disease, other chronic inflammatory and autoimmune / inflammatory diseases, chronic heart disease, polycystic ovary syndrome, preeclampsia, and cancer.

20. A pharmaceutical composition comprising a compound according to claim 1 as the active ingredient.

21. The pharmaceutical composition according claim 20, further comprising at least one additional active ingredient or a pharmaceutically acceptable carrier.

22. A method for the prophylaxis or treatment of disorders acting on the fatty acid binding protein FABP4, which comprises administering to a subject in need of such treatment an effective amount of a compound according to claim 1.

23. A method according to claim 22, wherein the subject is a human.